AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17666348 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil injections combined with TSQ and basic treatment
Number of subjects: 120
Study 17666348 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (control group)
Number of subjects: 120
Study 15310631 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 mL (Placebo)
Number of subjects: 118
Study 15310631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg.kg(‐1)
Number of subjects: 118
Study 15310631 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.6 mg.kg(‐1)
Number of subjects: 118
Study 15310631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 5 mg
Number of subjects: 118
Study 11692217 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment (high dose)
Number of subjects: 19
Study 11692217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC treatment)
Number of subjects: 19
Study 9131324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg once-daily
Number of subjects: 752
Study 9131324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg b.i.d.
Number of subjects: 752
Study 9131324 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 13.3 mg/kg t.i.d.
Number of subjects: 752
Study 8176568 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and chlorothiazide
Number of subjects: 43
Study 8176568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 2962954 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 50
Study 2962954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28989074 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus active rehabilitation (in-clinic subsymptom threshold aerobic training, coordination exercises, visualization and imagery techniques with a physiotherapist, mean 3.4 sessions, over 6 weeks)
Number of subjects: 19
Study 28989074 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 19
Study 28989074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation
Number of subjects: 19
Study 26541230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty with intraoperative calcar fracture
Number of subjects: 2913
Study 26541230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcar fractures)
Number of subjects: 2913
Study 25643864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Reading and in vivo rehearsal treatment
Number of subjects: 43
Study 25643864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 23663588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 150
Study 23663588 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 150
Study 19775500 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of cannabidiol (CBD)
Number of subjects: 15
Study 19775500 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Delta 9‐tetrahydrocannabinol (Delta 9‐THC)
Number of subjects: 15
Study 19775500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18403122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (26.8 microg ED(50) in Group A, 17.7 microg ED(50) in Group G)
Number of subjects: 224
Study 18403122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (27.4 microg ED(50) in Group A, 12.8 microg ED(50) in Group G)
Number of subjects: 224
Study 16899804 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral internet program
Number of subjects: 57
Study 16899804 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study 12660911 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized placebo-controlled trial of an injectable medicine given throughout pregnancy
Number of subjects: 50
Study 12660911 — intervention group
Group type: COMPARATOR
Intervention: Declining participation in the trial
Number of subjects: 50
Study 14967373 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg p.o. t.i.d. for 6 months
Number of subjects: 29
Study 10490154 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 60
Study 10490154 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg intrathecal morphine
Number of subjects: 60
Study 7581719 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 100 micrograms b.i.d.
Number of subjects: 23
Study 7581719 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 micrograms b.i.d.
Number of subjects: 23
Study 7581719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2379594 — intervention group
Group type: EXPERIMENTAL
Intervention: Metachronous metastases resection
Number of subjects: 122
Study 2379594 — intervention group
Group type: COMPARATOR
Intervention: Synchronous metastases resection
Number of subjects: 122
Study 205382 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25(OH)2D3) at a mean dose of 0.579 microgram/day for 3 months
Number of subjects: 22
Study 205382 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 at a mean dose of 706 IU/day
Number of subjects: 22
Study 31180926 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 0 to 7 days (N = 675)
Number of subjects: 1330
Study 31180926 — intervention group
Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8 to 14 days (N = 655)
Number of subjects: 1330
Study 28577691 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization at index admission
Number of subjects: 296
Study 28577691 — intervention group
Group type: COMPARATOR
Intervention: IRA-only P-PCI
Number of subjects: 296
Study 25881046 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus Chloroquine (AZCQ)
Number of subjects: 255
Study 25881046 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 255
Study 24072504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dietary tryptophan depletion (ATD)
Number of subjects: 18
Study 24072504 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid load (BAL)
Number of subjects: 18
Study 21857969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention in a randomized clinical trial of pharmaceutical care
Number of subjects: 56
Study 21857969 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent patients (n=12)
Number of subjects: 56
Study 21857969 — intervention group
Group type: COMPARATOR
Intervention: Adherent patients (n=44)
Number of subjects: 56
Study 19752847 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive music with conscious sedation
Number of subjects: 39
Study 19752847 — intervention group
Group type: COMPARATOR
Intervention: Control group with sedation
Number of subjects: 39
Study 17095420 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth Move (n = 42)
Number of subjects: 86
Study 17095420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 86
Study 14747881 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg o.d.
Number of subjects: 144
Study 14747881 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg o.d.
Number of subjects: 144
Study 11320181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 0
Study 11320181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9219204 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg BID (beta 1-antagonist)
Number of subjects: 7
Study 9219204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg BID (combined beta 1, beta 2-antagonist)
Number of subjects: 7
Study 9219204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9219204 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol
Number of subjects: 7
Study 7957426 — intervention group
Group type: COMPARATOR
Intervention: IVGG therapy
Number of subjects: 79
Study 7957426 — intervention group
Group type: COMPARATOR
Intervention: Low-dose PTX and IVGG combination therapy (10 mg/kg per day)
Number of subjects: 79
Study 7957426 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose PTX and IVGG combination therapy (20 mg/kg per day)
Number of subjects: 79
Study 31150295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Adolescents (PE-A)
Number of subjects: 61
Study 31150295 — intervention group
Group type: COMPARATOR
Intervention: Client-Centered Therapy (CCT)
Number of subjects: 61
Study 30389037 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise training (three 45-min sessions per week for 8 weeks)
Number of subjects: 40
Study 30389037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lifestyle changes)
Number of subjects: 40
Study 26171942 — intervention group
Group type: COMPARATOR
Intervention: Blood self-monitoring
Number of subjects: 181
Study 26171942 — intervention group
Group type: COMPARATOR
Intervention: Urine self-monitoring
Number of subjects: 181
Study 24552319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone-bacitracin-colistin eardrops
Number of subjects: 230
Study 24552319 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin-clavulanate suspension
Number of subjects: 230
Study 24552319 — intervention group
Group type: COMPARATOR
Intervention: Initial observation
Number of subjects: 230
Study 23856594 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery coach for substance-involved mothers
Number of subjects: 453
Study 23856594 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 453
Study 18955324 — intervention group
Group type: EXPERIMENTAL
Intervention: Satureja khuzestanica (250 mg dried leaves, once a day for 60 days)
Number of subjects: 21
Study 18955324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18853287 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (watching cartoon films)
Number of subjects: 300
Study 18853287 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 300
Study 18853287 — intervention group
Group type: COMPARATOR
Intervention: Control group (without any intervention)
Number of subjects: 300
Study 16883452 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 75
Study 16883452 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine plus neostigmine 4 ug kg‐1
Number of subjects: 75
Study 16883452 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus 1 ug kg‐1 fentanyl
Number of subjects: 75
Study 12680791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant whole brain radiation therapy (WBRT) with focal treatment (stereotactic radiosurgery or conventional surgery)
Number of subjects: 0
Study 12680791 — intervention group
Group type: COMPARATOR
Intervention: Focal treatment (stereotactic radiosurgery or conventional surgery)
Number of subjects: 0
Study 11016001 — intervention group
Group type: EXPERIMENTAL
Intervention: Azasetron plus dexamethasone
Number of subjects: 0
Study 11016001 — intervention group
Group type: COMPARATOR
Intervention: Azasetron alone
Number of subjects: 0
Study 8857326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TNS)
Number of subjects: 234
Study 8857326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 234
Study 1621152 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 1019
Study 1621152 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior surgery
Number of subjects: 1019
Study 1621152 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphotic deformity greater than 30 degrees
Number of subjects: 1019
Study 1621152 — intervention group
Group type: COMPARATOR
Intervention: Seat belts
Number of subjects: 1019
Study 1621152 — intervention group
Group type: COMPARATOR
Intervention: Fracture type
Number of subjects: 1019
Study 6546416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E (15 mg/kg on day 1, 10 mg/kg on days 2, 4, and 6)
Number of subjects: 168
Study 6546416 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E (100 mg/kg/d)
Number of subjects: 168
Study 6546416 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscular injections
Number of subjects: 168
Study 31374703 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distortion environment (robot-free, visual feedback)
Number of subjects: 0
Study 31374703 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29580213 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 854
Study 29580213 — intervention group
Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 854
Study 29580213 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 854
Study 26729760 — intervention group
Group type: EXPERIMENTAL
Intervention: IR dl‐MPH (0.3 mg/kg)
Number of subjects: 24
Study 26729760 — intervention group
Group type: COMPARATOR
Intervention: IR d‐MPH (0.15 mg/kg)
Number of subjects: 24
Study 25008878 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal lavage with porcine pulmonary surfactant (PS)
Number of subjects: 136
Study 25008878 — intervention group
Group type: COMPARATOR
Intervention: Intratracheal injection of porcine pulmonary surfactant (PS)
Number of subjects: 136
Study 22569045 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine after Listerine mouthwash
Number of subjects: 120
Study 22569045 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 120
Study 22569045 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 120
Study 19765953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d of calcium intake during bedrest (study A)
Number of subjects: 17
Study 19765953 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg/d of calcium intake during bedrest (study B)
Number of subjects: 17
Study 19765953 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory control phase (for both studies)
Number of subjects: 17
Study 18808597 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nurse assessment of falls-and-fracture risk factors and home hazards, referral to appropriate community interventions, and strength and balance exercise program
Number of subjects: 312
Study 18808597 — intervention group
Group type: COMPARATOR
Intervention: Usual care and social visits
Number of subjects: 312
Study 16022169 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments (multiple)
Number of subjects: 0
Study 16022169 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study 12383065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0
Study 10439731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2% plus 67% nitrous oxide)
Number of subjects: 24
Study 10439731 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.2% plus 67% nitrous oxide)
Number of subjects: 24
Study 7557866 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA/MTX (Ursodeoxycholic acid 13 to 15 mg/kg/d and Methotrexate 0.25 mg/kg/wk)
Number of subjects: 32
Study 7557866 — intervention group
Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 32
Study 7557866 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 32
Study 2265237 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg PPA HCl CR caplet once daily for 4 days
Number of subjects: 12
Study 2265237 — intervention group
Group type: COMPARATOR
Intervention: 25 mg PPA HCl solution three times a day for 4 days
Number of subjects: 12
Study 2265237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study 388402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg once and twice daily
Number of subjects: 0
Study 388402 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg once and twice daily
Number of subjects: 0
Study 31470813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil
Number of subjects: 40
Study 31470813 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 40
Study 30030717 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic 270 degree posterior fundoplication (LTF)
Number of subjects: 20
Study 30030717 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic 180 degree anterior fundoplication (LAF)
Number of subjects: 20
Study 27001081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 FiO2 (80% oxygen concentration)
Number of subjects: 40
Study 27001081 — intervention group
Group type: COMPARATOR
Intervention: 0.4 FiO2 (40% oxygen concentration)
Number of subjects: 40
Study 27001081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 25266438 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (1 or 2 mg for ages 6-11 years; 2 or 3 mg for ages 12-17 years)
Number of subjects: 486
Study 25266438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 25266438 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 486
Study 22917728 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon plus bare metal stent (DCB/BMS)
Number of subjects: 55
Study 22917728 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (DES)
Number of subjects: 55
Study 20184226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole formulations in biorelevant medium using USP apparatus 2
Number of subjects: 0
Study 20184226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole formulations in biorelevant medium using USP apparatus 3
Number of subjects: 0
Study 20184226 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dissolution profiles
Number of subjects: 0
Study 18042869 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection-infusion with levobupivacaine
Number of subjects: 154
Study 18042869 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection-infusion
Number of subjects: 154
Study 17130031 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 38) received 1 g paracetamol and 100 mg diclofenac
Number of subjects: 74
Study 17130031 — intervention group
Group type: COMPARATOR
Intervention: Group B (n = 36) received 1 g paracetamol only
Number of subjects: 74
Study 14595274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg once daily
Number of subjects: 24
Study 14595274 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 200 microg twice daily
Number of subjects: 24
Study 10335995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (3 x 100 mg Fe2+ per day for 5 weeks before operation)
Number of subjects: 123
Study 10335995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg Fe3+ after each donation with initial i.v. iron supplementation for hemoglobin under 15 g/dL)
Number of subjects: 123
Study 10335995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron medication)
Number of subjects: 123
Study 8565027 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP AQ Forte (0.084%) nasal spray 336 micrograms once daily
Number of subjects: 64
Study 8565027 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP AQ (0.042%) nasal spray 168 micrograms twice daily
Number of subjects: 64
Study 8565027 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray twice daily
Number of subjects: 64
Study 8565027 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 10 mg once daily in the morning
Number of subjects: 64
Study 1687999 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study 1687999 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg)
Number of subjects: 12
Study 1687999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6750252 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 rad total body irradiation (TBI) in a single exposure
Number of subjects: 24
Study 6750252 — intervention group
Group type: COMPARATOR
Intervention: 1200 rad TBI fractionated over six days
Number of subjects: 24
Study 6750252 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients transplanted in second remission
Number of subjects: 24
Study 6750252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients transplanted in second remission
Number of subjects: 24
Study 6750252 — intervention group
Group type: COMPARATOR
Intervention: Patients transplanted in relapse
Number of subjects: 24
Study 31876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported total physical activity (PA)
Number of subjects: 103
Study 31876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching television
Number of subjects: 103
Study 31876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 103
Study 31876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 103
Study 31876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 103
Study 31876665 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and sedentary behavior
Number of subjects: 103
Study 30808365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 0
Study 30808365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 30808365 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 29738177 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic spermatic vein ligation
Number of subjects: 120
Study 29738177 — intervention group
Group type: COMPARATOR
Intervention: Conventional open high ligation
Number of subjects: 120